Ignite Creation Date:
2024-05-06 @ 9:18 AM
Last Modification Date:
2024-10-26 @ 12:12 PM
Study NCT ID:
NCT02950870
Status:
UNKNOWN
Last Update Posted:
2016-11-01
First Post:
2016-10-26
Brief Title:
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection
Sponsor:
University of Modena and Reggio Emilia
Organization:
University of Modena and Reggio Emilia
Study Overview
Official Title:
An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin RBV in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus HCV Infection
Status:
UNKNOWN
Status Verified Date:
2016-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral treatment
Detailed Description:
The study is interventional controlled randomized block 21 case controls in open label
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None